<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441008</url>
  </required_header>
  <id_info>
    <org_study_id>202002608</org_study_id>
    <nct_id>NCT04441008</nct_id>
  </id_info>
  <brief_title>Accelerated iTBS for Depression and Suicidality</brief_title>
  <acronym>RAPID</acronym>
  <official_title>Radical aiTBS Protocol for Intractable Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this current study is to evaluate the feasibility, safety, and
      tolerability of &quot;high dose&quot; aiTBS in psychiatric inpatient and outpatients with
      treatment-refractory unipolar, non-psychotic major depressive disorder, using patients
      receiving ECT as an active comparator. Developing a better understanding of the feasibility
      and tolerability of adapting this treatment to an acutely ill patient population could lead
      to huge breakthroughs for clinician decision-making and for the further optimization of brain
      stimulation depression protocols. The results of this study can help guide future
      confirmatory efficacy trials of high-dose aiTBS by providing a better understanding of how
      feasibility, safety and tolerability compare to ECT, as well as unforeseen challenges of its
      use.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-blind with crossover of experimental (aiTBS) group into standard of care (ECT) group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigator and outcomes assessor will be blinded to patient's designation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate at completion of aiTBS vs the ECT group</measure>
    <time_frame>5 days</time_frame>
    <description>The primary tolerability endpoint is the proportion of aiTBS or ECT patients completing the protocol to a degree thought to be satisfactory for achieving the intended antidepressant effect. Completion for aiTBS arm is defined as completion of at least 60% of the treatment protocol (30 of 50 treatments) with treatments on at least 60% of days (3 of 5 days during the week). Completion for ECT arm is defined as completion of at least 2 of 3 ECT treatments during the first week.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Suicide</condition>
  <arm_group>
    <arm_group_label>aiTBS arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aiTBS treatment as lead-in phase to ECT standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ECT as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accelerated Intermittent Theta Burst (aiTBS)</intervention_name>
    <description>High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.</description>
    <arm_group_label>aiTBS arm</arm_group_label>
    <other_name>SAINT Protocol, accelerated TMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electroconvulsive therapy (ECT)</intervention_name>
    <description>ECT as per standard clinical care and management.</description>
    <arm_group_label>ECT arm</arm_group_label>
    <arm_group_label>aiTBS arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Ability to provide informed consent

               -  Availability for the duration of the study and willingness to comply with all
                  study procedures

               -  Age 18 to 90

               -  Diagnosis of major depressive disorder by DSM-5 criteria

               -  Depressive symptoms are thought to be caused primarily by a major depressive
                  episode and not by some other neurologic or psychiatric illness

               -  Failure of or intolerance to at least 2 antidepressant treatments of different
                  therapeutic classes (can include psychotherapy trial or neurostimulation trial)

               -  Meets criteria for clinical eligibility for ECT treatment, including optimization
                  of any medical conditions and completion of any medical testing or clearance as
                  clinically indicated

               -  Able to consent voluntarily to treatment

               -  Score of at least 2 on the MADRS item 10

               -  Ability to sit or lie down for an extended period of time and willingness to
                  adhere to the theta burst stimulation protocol

        Exclusion Criteria:

          -  • Presence of implanted ferromagnetic devices or materials, including cardiac
             pacemaker, cochlear implant, deep brain stimulation device, vagus nerve stimulation
             device, shrapnel, facial or scalp piercings that cannot be removed, or metallic face
             or head tattoos

               -  Pregnancy or lactation

               -  Previous bad reaction or intolerance to transcranial magnetic stimulation

               -  Febrile illness within 1 week

               -  Treatment with another investigational drug or other intervention within 30 days

               -  Recent substance abuse or use disorder within the past 6 months, excluding
                  tobacco or infrequent cannabis use

               -  History of epilepsy or seizure disorder

               -  History of penetrating traumatic brain injury, multiple sclerosis, or history of
                  brain surgery or intracranial hemorrhage

               -  Primary psychiatric or medical/neurologic illness other than MDD that is more
                  likely to account for depressive symptoms, including severe personality disorder
                  or psychotic illness

               -  Severe or moderate intellectual disability

               -  Major neurocognitive disorder

               -  Involuntary commitment or petition filed for involuntary ECT treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Trapp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Pace, MS</last_name>
    <phone>(319) 384-9302</phone>
    <email>benjamin-pace@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Trapp, MD</last_name>
    <phone>(319) 467-8188</phone>
    <email>nicholas-trapp@uiowa.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016 May-Jun;9(3):336-346. doi: 10.1016/j.brs.2016.03.010. Epub 2016 Mar 16. Review.</citation>
    <PMID>27090022</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.</citation>
    <PMID>25655160</PMID>
  </reference>
  <reference>
    <citation>George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46.</citation>
    <PMID>20439832</PMID>
  </reference>
  <reference>
    <citation>Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692. doi: 10.1016/S0140-6736(18)30295-2. Epub 2018 Apr 26. Erratum in: Lancet. 2018 Jun 23;391(10139):e24.</citation>
    <PMID>29726344</PMID>
  </reference>
  <reference>
    <citation>Peng Z, Zhou C, Xue S, Bai J, Yu S, Li X, Wang H, Tan Q. Mechanism of Repetitive Transcranial Magnetic Stimulation for Depression. Shanghai Arch Psychiatry. 2018 Apr 25;30(2):84-92. doi: 10.11919/j.issn.1002-0829.217047. Review.</citation>
    <PMID>29736128</PMID>
  </reference>
  <reference>
    <citation>Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain. 2018 Mar 1;141(3):e18. doi: 10.1093/brain/awx379.</citation>
    <PMID>29415152</PMID>
  </reference>
  <reference>
    <citation>Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. JAMA. 2017 Apr 18;317(15):1517. doi: 10.1001/jama.2017.3826.</citation>
    <PMID>28418490</PMID>
  </reference>
  <reference>
    <citation>Zhan Y, Zhang B, Zhou Y, Zheng W, Liu W, Wang C, Li H, Chen L, Yu L, Walter M, Li M, Li MD, Ning Y. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019 May 15;251:205-212. doi: 10.1016/j.jad.2019.03.071. Epub 2019 Mar 22.</citation>
    <PMID>30927581</PMID>
  </reference>
  <reference>
    <citation>Baeken C. Accelerated rTMS: A Potential Treatment to Alleviate Refractory Depression. Front Psychol. 2018 Oct 31;9:2017. doi: 10.3389/fpsyg.2018.02017. eCollection 2018.</citation>
    <PMID>30429807</PMID>
  </reference>
  <reference>
    <citation>Feffer K, Lee HH, Mansouri F, Giacobbe P, Vila-Rodriguez F, Kennedy SH, Daskalakis ZJ, Blumberger DM, Downar J. Early symptom improvement at 10 sessions as a predictor of rTMS treatment outcome in major depression. Brain Stimul. 2018 Jan - Feb;11(1):181-189. doi: 10.1016/j.brs.2017.10.010. Epub 2017 Oct 19.</citation>
    <PMID>29107623</PMID>
  </reference>
  <reference>
    <citation>Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002 Nov;72(2):177-84.</citation>
    <PMID>12200208</PMID>
  </reference>
  <reference>
    <citation>Kerner N, Prudic J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry (London). 2014 Feb;4(1):33-54.</citation>
    <PMID>24778709</PMID>
  </reference>
  <reference>
    <citation>Guse B, Falkai P, Wobrock T. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna). 2010 Jan;117(1):105-22. doi: 10.1007/s00702-009-0333-7. Epub 2009 Oct 27. Review.</citation>
    <PMID>19859782</PMID>
  </reference>
  <reference>
    <citation>George MS, Raman R, Benedek DM, Pelic CG, Grammer GG, Stokes KT, Schmidt M, Spiegel C, Dealmeida N, Beaver KL, Borckardt JJ, Sun X, Jain S, Stein MB. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul. 2014 May-Jun;7(3):421-31. doi: 10.1016/j.brs.2014.03.006. Epub 2014 Mar 19.</citation>
    <PMID>24731434</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Nicholas Trapp</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>transcranial magnetic stimulation, theta burst, accelerated TMS, ECT, electroconvulsive therapy, depression, suicidality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

